Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty and incident cognitive impairment in patients with CKD: sex-frailty paradox in the Chronic Renal Insufficiency Cohort (CRIC).

GeroScience·2026
Same author

Pregnancy and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Journal of the American Society of Nephrology : JASN·2026
Same author

Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease.

Kidney & blood pressure research·2026
Same author

KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

Renal blood flow and progression to kidney failure in ADPKD.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing.

The Journal of physiology·2026

Related Experiment Videos

Beta-blockade in chronic dialysis patients.

Seth B Furgeson1, Michel Chonchol

  • 1Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA.

Seminars in Dialysis
|February 7, 2008
PubMed
Summary

Cardiovascular diseases (CVD) cause half of deaths in dialysis patients. Beta-blockers may help, but their effectiveness and safety in this population require further investigation.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular diseases (CVD) are a leading cause of mortality in chronic dialysis patients, accounting for approximately 50% of deaths.
  • Sudden cardiac death is prevalent, representing 60% of cardiac deaths in this population, often linked to conditions like cardiomyopathy, coronary artery disease, and arrhythmia.
  • Despite dialysis advancements, CVD mortality remains high due to a lack of evidence-based strategies for managing cardiac conditions.

Purpose of the Study:

  • To review the role of sympathetic nervous system activation in the pathogenesis of cardiovascular diseases in chronic kidney disease (CKD) patients.
  • To evaluate the potential benefits and risks of beta-blocker therapy in patients undergoing chronic dialysis.
  • To address the uncertainty surrounding beta-blocker efficacy and usage in the dialysis population.

Related Experiment Videos

Main Methods:

  • Literature review focusing on sympathetic nervous system activation in kidney disease.
  • Analysis of studies investigating beta-blocker use in patients with advanced chronic kidney disease and on dialysis.
  • Examination of potential benefits (e.g., reducing cardiovascular morbidity and mortality) versus risks (e.g., hypotension, bradycardia, hyperkalemia).

Main Results:

  • Sympathetic adrenergic system activation is a documented issue in chronic dialysis patients, contributing to cardiac pathologies.
  • Beta-blockers have demonstrated benefits in non-dialysis patients with similar cardiac conditions.
  • Evidence regarding the efficacy and safety of beta-blockers in the chronic dialysis population remains unclear, with concerns about suboptimal usage.

Conclusions:

  • Beta-blockers present a potential therapeutic option for reducing cardiovascular risk in dialysis patients due to sympathetic overactivity.
  • However, the specific benefits and risks, including side effects like hypotension and hyperkalemia, need careful consideration in this vulnerable group.
  • Further research is essential to clarify the role and optimize the use of beta-blockers in patients with advanced chronic kidney disease undergoing dialysis.